Compare CLMT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | AGIO |
|---|---|---|
| Founded | 1916 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2024 | 2013 |
| Metric | CLMT | AGIO |
|---|---|---|
| Price | $33.99 | $28.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $28.65 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 865.0K | 856.8K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,137,100,000.00 | $43,011,000.00 |
| Revenue This Year | $3.94 | $76.75 |
| Revenue Next Year | $1.07 | $170.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.70 | $22.24 |
| 52 Week High | $36.94 | $46.00 |
| Indicator | CLMT | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.05 | 48.36 |
| Support Level | $30.29 | $26.42 |
| Resistance Level | $36.78 | $29.37 |
| Average True Range (ATR) | 1.39 | 0.95 |
| MACD | 0.09 | 0.16 |
| Stochastic Oscillator | 55.06 | 63.67 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.